When is the next results date for Bharat Rasayan?

No Upcoming Board Meetings

Has Bharat Rasayan declared dividend?

Yes, Bharat Rasayan Ltd. has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of September 12, 2024. However, the company has experienced significant declines in price returns over various periods, indicating challenges in stock performance despite the dividend announcement.

Bharat Rasayan Ltd. has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 12 Sep 24<BR><BR>Dividend Yield: 0.02%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.48%, with a dividend return of 0%, resulting in a total return of -22.48%.<BR><BR>Over the past year, the price return was -14.14%, with a dividend return of 0.01%, leading to a total return of -14.13%.<BR><BR>In the 2-year period, the price return was -9.81%, with a dividend return of 0.03%, resulting in a total return of -9.78%.<BR><BR>For the 3-year period, the price return was -23.53%, with a dividend return of 0.04%, leading to a total return of -23.49%.<BR><BR>In the last 4 years, the price return was -31.16%, with a dividend return of 0.05%, resulting in a total return of -31.11%.<BR><BR>Over the 5-year period, the price return was 27.37%, with a dividend return of 0.10%, leading to a total return of 27.47%.<BR><BR>Overall, while Bharat Rasayan has declared a dividend, the total returns over various periods show significant declines in price returns, particularly in the shorter time frames, suggesting challenges in stock performance despite the dividend declaration.

Who are the peers of the Bharat Rasayan?

Bharat Rasayan's peers include P I Industries, UPL, Bayer CropSci., and others, with varying management and growth ratings. Notably, NACL Industries has the highest 1-year return at 163.56%, while Bharat Rasayan has the lowest at -12.17%.

Peers: The peers of Bharat Rasayan are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, NACL Industries, Insecticid.India, India Pesticides, Meghmani Organi., and Punjab Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci., Dhanuka Agritech, and the rest have Good management risk, including Bharat Rasayan and Sumitomo Chemi. Average management risk is found at UPL, NACL Industries, and Insecticid.India, while Meghmani Organi. has Below Average management risk. Growth ratings show that P I Industries has Excellent growth, while Dhanuka Agritech and the rest have Below Average growth, including Bharat Rasayan, UPL, Bayer CropSci., Sumitomo Chemi., NACL Industries, Insecticid.India, India Pesticides, and Meghmani Organi. Capital Structure ratings are Excellent for Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Bharat Rasayan, and Insecticid.India, while Average is noted for Punjab Chemicals and Below Average for UPL, NACL Industries, and Meghmani Organi.<BR><BR>Return Snapshot: The peer with the highest 1-year return is NACL Industries at 163.56%, while Bharat Rasayan has the lowest at -12.17%. Compared to its peers, Bharat Rasayan's return is significantly lower. Additionally, the six-month return is negative for Bharat Rasayan, UPL, Sumitomo Chemi., and Meghmani Organi.

Who are in the management team of Bharat Rasayan?

As of March 2022, the management team of Bharat Rasayan includes S N Gupta (Chairman & Managing Director), Mahabir Prasad Gupta, Rajender Prasad Gupta, Ajay Gupta, Kamleshwar Prasad Uniyal (all Executive Directors), and several Independent Non-Executive Directors, along with Nikita Chadha as Company Secretary. This team combines executive leadership with independent oversight for effective governance.

As of March 2022, the management team of Bharat Rasayan includes the following members:<BR><BR>1. S N Gupta - Chairman & Managing Director<BR>2. Mahabir Prasad Gupta - WTD & Executive Director<BR>3. Rajender Prasad Gupta - WTD & Executive Director<BR>4. Ajay Gupta - Executive Director & Wholetime Director<BR>5. Kamleshwar Prasad Uniyal - Executive Director<BR>6. Pankaj Gupta - Independent Non-Executive Director<BR>7. Ram Kanwar - Independent Non-Executive Director<BR>8. Sujata Agarwal - Independent Non-Executive Director<BR>9. Suresh Kumar Garg - Independent Non-Executive Director<BR>10. Ankit Aggarwal - Independent Non-Executive Director<BR>11. Nikita Chadha - Company Secretary<BR><BR>This team encompasses a mix of executive and independent directors, contributing to the governance and management of the company.

What does Bharat Rasayan do?

Bharat Rasayan Ltd. is a small-cap company in the pesticides and agrochemicals industry, specializing in technical grade pesticides and intermediates. As of March 2025, it reported net sales of ₹3,065 Cr and a net profit of ₹251 Cr, with a market cap of ₹4,855 Cr.

Overview:<BR>Bharat Rasayan Ltd. is a small-cap company operating in the pesticides and agrochemicals industry, specializing in the manufacturing of technical grade pesticides and intermediates.<BR><BR>History:<BR>Bharat Rasayan Limited was incorporated as a Public Limited Company on May 15, 1989. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 3,065 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 251 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 4,855 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 34.00 <BR>Industry P/E: 40 <BR>Dividend Yield: 0.01% <BR>Debt-Equity: -0.18 <BR>Return on Equity: 12.47% <BR>Price to Book: 4.19 <BR><BR>Contact Details:<BR>Address: 1501 Vikram Tower, Rajendra Place New Delhi New Delhi : 110008 <BR>Tel: 91-11-41538383/43661111 <BR>Email: invester.brl@bharatgroup.co.in <BR>Website: http://www.bharatgroup.co.in

Who are the top shareholders of the Bharat Rasayan?

The top shareholders of Bharat Rasayan include Sat Narain Gupta, the largest promoter with 23.83%, followed by Ritesh Stock Broking Private Limited at 4.72%, mutual funds with 2.55%, and foreign institutional investors holding 0.49%. Individual investors collectively own 11.23% of the shares.

The top shareholders of Bharat Rasayan include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sat Narain Gupta, with 23.83%. Additionally, Ritesh Stock Broking Private Limited is the highest public shareholder, owning 4.72%. The company also has mutual funds holding 2.55% through two schemes, and foreign institutional investors (FIIs) hold 0.49% across 32 entities. Individual investors collectively own 11.23% of the shares.

How big is Bharat Rasayan?

As of 24th July, Bharat Rasayan Ltd. has a market capitalization of 4,649.00 Cr, with recent Net Sales of 1,173.00 Cr and a Net Profit of 140.92 Cr. The latest balance sheet shows Shareholder's Funds of 987.88 Cr and Total Assets of 1,197.45 Cr.

As of 24th July, Bharat Rasayan Ltd. has a market capitalization of 4,649.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Bharat Rasayan reported Net Sales of 1,173.00 Cr and a Net Profit of 140.92 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 987.88 Cr and Total Assets of 1,197.45 Cr.

Is Bharat Rasayan overvalued or undervalued?

As of August 11, 2025, Bharat Rasayan is considered very expensive and overvalued with a PE ratio of 33.63, elevated valuation metrics compared to industry norms, and a PEG ratio of 0.71, despite outperforming the Sensex in the short term.

As of 11 August 2025, Bharat Rasayan's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 33.63, an EV to EBITDA of 25.95, and a Price to Book Value of 4.19, which are all elevated compared to industry norms.<BR><BR>In comparison to its peers, Bharat Rasayan's PE ratio is lower than P I Industries at 35.18 and Bayer CropScience at 42.61, but higher than UPL, which has a PE of 34.55. The PEG ratio of 0.71 suggests some growth potential, yet the overall high valuation metrics indicate that the stock may not offer a favorable risk-reward profile at this time. Notably, while Bharat Rasayan has outperformed the Sensex in the short term, its longer-term performance has lagged, further supporting the view that it is currently overvalued.

Are Bharat Rasayan latest results good or bad?

Bharat Rasayan's latest results are considered negative, with a 13.25% decline in net profit and a 12.78% drop in net sales year-on-year, alongside the lowest operating margin in eight quarters at 11.56%. These factors have led to unfavorable market reactions and concerns about the company's future profitability.

Bharat Rasayan's latest results for the quarter ending September 2025 indicate a challenging performance. The company reported a consolidated net profit of ₹27.88 crores, which reflects a decline of 13.25% year-on-year. Additionally, net sales fell to ₹285.96 crores, marking a significant decrease of 12.78% compared to the same quarter last year. <BR><BR>The operating margin has also deteriorated, dropping to 11.56%, the lowest it has been in eight quarters. This margin compression suggests that the company is facing significant operational challenges, including rising input costs and competitive pressures in the agrochemical sector.<BR><BR>Overall, the results are generally viewed as negative, with the market reacting unfavorably, leading to a decline in the stock price following the announcement. The combination of declining revenues, shrinking margins, and a lack of growth in return metrics raises concerns about the company's future profitability and operational health.

How has been the historical performance of Bharat Rasayan?

Bharat Rasayan's historical performance shows fluctuating financial metrics, with net sales increasing to 1,173.00 Cr in March 2025 but declining from 1,234.34 Cr in March 2023. Despite rising costs, operating profit improved to 200.90 Cr, and profit after tax rose to 125.10 Cr, indicating a mixed performance with growth in sales and profits.

Answer:<BR>The historical performance of Bharat Rasayan shows fluctuations in key financial metrics over the years, with notable trends in revenue, profit, and assets.<BR><BR>Breakdown:<BR>Bharat Rasayan's net sales reached 1,173.00 Cr in March 2025, an increase from 1,044.63 Cr in March 2024, but a decline from 1,234.34 Cr in March 2023. The total operating income followed a similar trend, peaking at 1,301.15 Cr in March 2022 before decreasing in subsequent years. The company's total expenditure, excluding depreciation, was 998.12 Cr in March 2025, up from 927.36 Cr in March 2024, reflecting rising raw material costs which were 824.54 Cr in March 2025. Operating profit (PBDIT) was 200.90 Cr in March 2025, showing an increase from 138.17 Cr in March 2024, although it was lower than the 266.67 Cr recorded in March 2022. Profit before tax stood at 169.19 Cr in March 2025, compared to 109.42 Cr in March 2024, while profit after tax was 125.10 Cr, up from 81.61 Cr in the previous year. The company's total assets increased to 1,408.14 Cr in March 2025 from 1,197.45 Cr in March 2024, with total liabilities also rising to 1,408.14 Cr. Cash flow from operating activities improved to 172.00 Cr in March 2025, up from 41.00 Cr in March 2024, indicating a positive cash flow trend. Overall, Bharat Rasayan's financial performance reflects a mix of growth in sales and profits alongside rising costs and liabilities.

Should I buy, sell or hold Bharat Rasayan?

Is Bharat Rasayan technically bullish or bearish?

As of November 26, 2025, the trend is mildly bullish with supportive MACD signals, but caution is advised due to bearish weekly KST and Bollinger Bands, alongside a lack of momentum in the RSI.

As of 26 November 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by bullish MACD signals on both the weekly and monthly time frames, and a bullish daily moving average. However, the weekly KST is mildly bearish and the Bollinger Bands indicate a sideways trend on the weekly, with a bearish monthly outlook. The RSI shows no signals on both time frames, indicating a lack of momentum. Overall, while there are bullish indicators, the presence of bearish signals in other areas suggests caution.

Which are the latest news on Bharat Rasayan?

Why is Bharat Rasayan falling/rising?

As of 03-Dec, Bharat Rasayan Ltd. is seeing a slight rise in its stock price to 10,446.95, attributed to short-term performance, but it has poor long-term growth with declining profits and significant underperformance over the past year. Despite some positive financial indicators, the overall outlook remains mixed due to falling investor participation.

As of 03-Dec, Bharat Rasayan Ltd. is experiencing a slight rise in its stock price, currently at 10,446.95, with a change of 21.15 (0.2%) upwards. This increase can be attributed to its performance today, where it outperformed its sector by 0.57%. Additionally, the stock is trading higher than its 5-day, 50-day, and 200-day moving averages, indicating some positive momentum in the short term.<BR><BR>However, despite this recent uptick, the stock has shown poor long-term growth, with a decline in operating profit at an annual rate of -3.05% over the last five years. The net sales for the recent quarter fell by -12.78%, and the profit after tax also decreased by -13.3%. Furthermore, the stock has generated a return of -11.20% over the past year, indicating significant underperformance compared to broader market indices like the Sensex, which has increased by 5.27% in the same period.<BR><BR>The company does exhibit some positive factors, such as a high return on equity (ROE) of 15.82% and a low debt-to-equity ratio of 0.02 times, which suggests financial stability. However, the overall picture remains mixed, with falling investor participation evidenced by a decrease in delivery volume by -18.7% against the 5-day average. This decline in participation, combined with the company's poor long-term growth metrics, suggests that while there may be short-term gains, the stock's long-term outlook remains concerning.